Legato Capital Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.37M Sell
37,430
-8,558
-19% -$310K 0.12% 262
2026
Q2
$1.63M Buy
45,988
+1,132
+3% +$33.5K 0.13% 228
2026
Q1
$1.24M Sell
44,856
-484
-1% -$12.4K 0.11% 239
2025
Q4
$984K Buy
45,340
+13,135
+41% +$259K 0.08% 364
2025
Q3
$487K Buy
+32,205
New +$399K 0.05% 443
2024
Q1
– Sell
-18,000
Closed -$202K – 607
2023
Q4
$202K Sell
18,000
-46,763
-72% -$456K 0.03% 529
2023
Q3
$756K Buy
64,763
+4,403
+7% +$49.8K 0.11% 301
2023
Q2
$608K Buy
+60,360
New +$540K 0.08% 376

Other funds holding ROIV

Legato Capital Management's ROIV Position: Q3 2026 in Review

Legato Capital Management reduced its Roivant Sciences (ROIV) stake by 19% in Q3 2026, selling an estimated $310K and leaving 37,430 shares worth $1.37M. The position accounts for 0.12% of the portfolio, ranked #262.

Legato Capital Management first reported a position in ROIV in Q2 2023 and has held it in 8 quarters since. The position peaked at $1.63M in Q2 2026. 522 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • Legato Capital Management held 37,430 shares of Roivant Sciences worth $1.37M as of Q3 2026.
  • Legato Capital Management sold 8,558 Roivant Sciences shares in Q3 2026, an estimated $310K.
  • Roivant Sciences made up 0.12% of Legato Capital Management's portfolio in Q3 2026, its #262 holding.
  • Legato Capital Management first reported a position in Roivant Sciences in Q2 2023 and has held it in 8 quarters since.
  • Legato Capital Management's Roivant Sciences position peaked at $1.63M in Q2 2026.
  • 522 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.